Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.

Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS.

JCI Insight. 2018 Jul 25;3(14). pii: 120594. doi: 10.1172/jci.insight.120594. [Epub ahead of print]

2.

Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.

Giles ED, Jindal S, Wellberg EA, Schedin T, Anderson SM, Thor AD, Edwards DP, MacLean PS, Schedin P.

Breast Cancer Res. 2018 Jun 14;20(1):50. doi: 10.1186/s13058-018-0974-2.

3.

Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer.

Wahdan-Alaswad RS, Edgerton SM, Salem HS, Thor AD.

J Oncol Transl Res. 2018;4(1). pii: 129. doi: 10.4172/2476-2261.1000129. Epub 2018 Mar 21.

4.

Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.

Lee H, Saini N, Howard EW, Parris AB, Ma Z, Zhao Q, Zhao M, Liu B, Edgerton SM, Thor AD, Yang X.

Sci Rep. 2018 May 1;8(1):6829. doi: 10.1038/s41598-018-25284-0.

5.

Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases.

Contreras-Zárate MJ, Ormond DR, Gillen AE, Hanna C, Day NL, Serkova NJ, Jacobsen BM, Edgerton SM, Thor AD, Borges VF, Lillehei KO, Graner MW, Kabos P, Cittelly DM.

Front Oncol. 2017 Nov 2;7:252. doi: 10.3389/fonc.2017.00252. eCollection 2017.

6.

Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.

Zhao M, Howard EW, Parris AB, Guo Z, Zhao Q, Ma Z, Xing Y, Liu B, Edgerton SM, Thor AD, Yang X.

Oncotarget. 2017 Jul 19;8(35):58847-58864. doi: 10.18632/oncotarget.19375. eCollection 2017 Aug 29.

7.

The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.

Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, MacLean PS, Anderson SM.

Horm Cancer. 2017 Dec;8(5-6):269-285. doi: 10.1007/s12672-017-0302-9. Epub 2017 Jul 24.

PMID:
28741260
8.

Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo.

Checkley LA, Rudolph MC, Wellberg EA, Giles ED, Wahdan-Alaswad RS, Houck JA, Edgerton SM, Thor AD, Schedin P, Anderson SM, MacLean PS.

Cancer Prev Res (Phila). 2017 Mar;10(3):198-207. doi: 10.1158/1940-6207.CAPR-16-0211-T. Epub 2017 Feb 2.

9.

Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.

Wahdan-Alaswad R, Harrell JC, Fan Z, Edgerton SM, Liu B, Thor AD.

Cell Cycle. 2016;15(8):1046-59. doi: 10.1080/15384101.2016.1152432.

10.

Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.

Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR.

Oncotarget. 2016 Mar 29;7(13):15757-71. doi: 10.18632/oncotarget.7462.

11.

Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).

Schneider BP, O'Neill A, Shen F, Sledge GW, Thor AD, Kahanic SP, Zander PJ, Davidson NE.

Br J Cancer. 2015 Dec 22;113(12):1651-7. doi: 10.1038/bjc.2015.405. Epub 2015 Dec 1.

12.

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.

Lyu H, Yang XH, Edgerton SM, Thor AD, Wu X, He Z, Liu B.

Oncotarget. 2016 Jan 19;7(3):2921-35. doi: 10.18632/oncotarget.6404.

13.
14.

Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b.

Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK.

Horm Cancer. 2014 Dec;5(6):374-89. doi: 10.1007/s12672-014-0188-8. Epub 2014 Sep 12.

15.

Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling.

Jindal S, Gao D, Bell P, Albrektsen G, Edgerton SM, Ambrosone CB, Thor AD, Borges VF, Schedin P.

Breast Cancer Res. 2014 Mar 28;16(2):R31. doi: 10.1186/bcr3633.

16.

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK.

Breast Cancer Res. 2014 Jan 22;16(1):R7. doi: 10.1186/bcr3599.

17.

Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.

Zhu P, Davis M, Blackwelder AJ, Bachman N, Liu B, Edgerton S, Williams LL, Thor AD, Yang X.

Cancer Prev Res (Phila). 2014 Feb;7(2):199-210. doi: 10.1158/1940-6207.CAPR-13-0181. Epub 2013 Dec 9.

18.

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.

Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.

Breast Cancer Res. 2013;15(5):R101.

19.

Glucose promotes breast cancer aggression and reduces metformin efficacy.

Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, Richer JK, Anderson SM, Thor AD.

Cell Cycle. 2013 Dec 15;12(24):3759-69. doi: 10.4161/cc.26641. Epub 2013 Oct 3.

20.

Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer.

Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, Tan AC, Schedin PS, Maclean PS.

Cancer Res. 2012 Dec 15;72(24):6490-501. doi: 10.1158/0008-5472.CAN-12-1653. Epub 2012 Dec 7.

21.

Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.

Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD.

Cell Cycle. 2012 Jan 15;11(2):367-76. doi: 10.4161/cc.11.2.18813. Epub 2012 Jan 15.

PMID:
22189713
22.

Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.

Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD.

Cell Cycle. 2011 Sep 1;10(17):2959-66. Epub 2011 Sep 1.

PMID:
21862872
23.

p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).

Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF; Cancer and Leukemia Group B.

Clin Cancer Res. 2011 Aug 1;17(15):5170-8. doi: 10.1158/1078-0432.CCR-11-0484. Epub 2011 Jun 21.

24.

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.

Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE.

Mol Cancer. 2010 Dec 20;9:317. doi: 10.1186/1476-4598-9-317.

25.

Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells.

Das PM, Thor AD, Edgerton SM, Barry SK, Chen DF, Jones FE.

Oncogene. 2010 Sep 16;29(37):5214-9. doi: 10.1038/onc.2010.271. Epub 2010 Jul 5.

26.

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.

Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B.

Cancer Res. 2010 Feb 1;70(3):1204-14. doi: 10.1158/0008-5472.CAN-09-3321. Epub 2010 Jan 26.

27.

Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation.

Yang X, Yang S, McKimmey C, Liu B, Edgerton SM, Bales W, Archer LT, Thor AD.

Carcinogenesis. 2010 Apr;31(4):695-702. doi: 10.1093/carcin/bgq007. Epub 2010 Jan 12.

PMID:
20067990
28.

Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.

Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X, Thor AD.

Mol Cancer Res. 2009 Nov;7(11):1882-92. doi: 10.1158/1541-7786.MCR-08-0509. Epub 2009 Oct 27.

29.

Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.

Thor AD, Edgerton SM, Jones FE.

Am J Pathol. 2009 Nov;175(5):1802-9. doi: 10.2353/ajpath.2009.090204. Epub 2009 Oct 1.

30.

Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.

Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L.

J Clin Oncol. 2009 Jul 20;27(21):3430-6. doi: 10.1200/JCO.2008.18.4085. Epub 2009 May 26.

31.

Metformin induces unique biological and molecular responses in triple negative breast cancer cells.

Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD.

Cell Cycle. 2009 Jul 1;8(13):2031-40. Epub 2009 Jul 21.

PMID:
19440038
32.

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro.

Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD.

Cell Cycle. 2009 Mar 15;8(6):909-15. Epub 2009 Mar 26.

PMID:
19221498
33.

The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.

Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE.

Cancer Res. 2008 Aug 1;68(15):6387-95. doi: 10.1158/0008-5472.CAN-08-0538.

34.

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD.

J Clin Oncol. 2008 May 10;26(14):2364-72. doi: 10.1200/JCO.2007.13.6580. Epub 2008 Apr 7.

PMID:
18390970
35.

HER2 and response to paclitaxel in node-positive breast cancer.

Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA; Cancer and Leukemia Group B (CALGB) Investigators.

N Engl J Med. 2007 Oct 11;357(15):1496-506.

36.

Bcl-2 overexpression sensitizes MCF-7 cells to genistein by multiple mechanisms.

Tophkhane C, Yang S, Bales W, Archer L, Osunkoya A, Thor AD, Yang X.

Int J Oncol. 2007 Oct;31(4):867-74.

PMID:
17786319
37.

Caspase expression profile and functional activity in a panel of breast cancer cell lines.

Yang S, Liu J, Thor AD, Yang X.

Oncol Rep. 2007 May;17(5):1229-35.

PMID:
17390070
38.

Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.

Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD.

Int J Cancer. 2007 May 1;120(9):1874-82.

39.

Caspase-3 mediated feedback activation of apical caspases in doxorubicin and TNF-alpha induced apoptosis.

Yang S, Thor AD, Edgerton S, Yang X.

Apoptosis. 2006 Nov;11(11):1987-97.

PMID:
17013758
40.

Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.

Mungamuri SK, Yang X, Thor AD, Somasundaram K.

Cancer Res. 2006 May 1;66(9):4715-24.

41.

Caspase 3 activation during herpes simplex virus 1 infection.

Kraft RM, Nguyen ML, Yang XH, Thor AD, Blaho JA.

Virus Res. 2006 Sep;120(1-2):163-75. Epub 2006 Apr 18.

PMID:
16621101
42.

Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.

Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD.

Breast Cancer Res. 2005;7(5):R708-18. Epub 2005 Jul 6.

43.

Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to radiation therapy.

Yang XH, Edgerton S, Thor AD.

Int J Oncol. 2005 Jun;26(6):1675-80.

PMID:
15870885
44.

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.

DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D 2nd, Thor AD.

J Clin Oncol. 2005 Feb 20;23(6):1152-60.

PMID:
15718311
45.

HER2 testing: laboratory, technical and clinical considerations.

Dressler LG, Thor AD.

Breast Dis. 2000;11:77-87.

PMID:
15687594
46.

Perinucleolar compartment prevalence has an independent prognostic value for breast cancer.

Kamath RV, Thor AD, Wang C, Edgerton SM, Slusarczyk A, Leary DJ, Wang J, Wiley EL, Jovanovic B, Wu Q, Nayar R, Kovarik P, Shi F, Huang S.

Cancer Res. 2005 Jan 1;65(1):246-53.

47.

Mammary tumor heterogeneity in wt-ErbB-2 transgenic mice.

Kosanke S, Edgerton SM, Moore D 2nd, Yang X, Mason T, Alvarez K, Jones L, Kim A, Thor AD.

Comp Med. 2004 Jun;54(3):280-7.

PMID:
15253274
48.

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.

Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge GW Jr.

J Clin Oncol. 2004 Mar 15;22(6):1071-7.

PMID:
15020608
49.

Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family.

Fong S, Mounkes L, Liu Y, Maibaum M, Alonzo E, Desprez PY, Thor AD, Kashani-Sabet M, Debs RJ.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14253-8. Epub 2003 Nov 11.

50.

erbB-2 (HER-2) and breast cancer progression.

Edgerton SM, Moore D 2nd, Merkel D, Thor AD.

Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):214-21.

PMID:
12966347

Supplemental Content

Support Center